Merck’s Keytruda receives European approval for two new indications in gynaecologic cancers: Rahway, New Jersey Friday, October 25, 2024, 09:00 Hrs [IST] Merck, known as MSD out ...

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Bicycle Therapeutics (BCYC – Research Report) yesterday and set a ...

When Terri Rau was diagnosed with breast cancer decades after being treated for Hodgkin lymphoma, she partnered with her ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for ...

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

From 2023 to 2033, Checkpoint Inhibitor Refractory Cancer sales are expected to flourish at a CAGR of 11.26%. By 2033, the ...

A partial clinical hold was placed on the registrational trial after results showed variance between squamous and ...